Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,361
  • Shares Outstanding, K 45,197
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,880 K
  • 60-Month Beta 1.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.01 +5.94%
on 10/16/19
1.23 -13.01%
on 09/19/19
-0.11 (-9.32%)
since 09/18/19
3-Month
1.01 +5.94%
on 10/16/19
1.29 -17.05%
on 09/18/19
-0.14 (-11.46%)
since 07/18/19
52-Week
0.78 +37.67%
on 04/01/19
3.15 -66.03%
on 04/22/19
-0.12 (-10.08%)
since 10/18/18

Most Recent Stories

More News
Due to Rising Prevalence of Cancer in U.S., Cancer Therapy Market Showing Rapid Growth

The global cancer therapy market looks like it will continue trend to continue its growth, worldwide. Cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific...

MBRX : 1.07 (-0.93%)
FCSC : 2.96 (unch)
NTEC : 0.73 (-2.70%)
MNK : 2.66 (+4.31%)
IMMU : 15.44 (-2.65%)
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.07 (-0.93%)
Cancer Drugs Projected to Generate the Most in Pharma Revenues

Cancer drug market revenues have been steadily rising in the past few years and all indicators predict that they will continue to rise over the next several years. According to industry sources, in 20118...

MBRX : 1.07 (-0.93%)
ARWR : 35.95 (-1.78%)
ABBV : 76.46 (+1.76%)
MNK : 2.66 (+4.31%)
NBRV : 1.99 (-2.93%)
Moleculin Announces CTRC Approval of WP1066 Pediatric Brain Tumor Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.07 (-0.93%)
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.07 (-0.93%)
Moleculin Completes Enrollment in Early-Stage Cancer Study

Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

BMY : 53.03 (+1.16%)
MRK : 84.68 (+1.05%)
SNGX : 0.88 (-4.30%)
MBRX : 1.07 (-0.93%)
Cancer Drug Sales Expected to Exceed $230 Billion by 2024

For decades, big (and small) pharma companies have been trying to find ways to cure or at least devise better treatments for all types of cancers. While the war has not been won to find a cure, there have...

MBRX : 1.07 (-0.93%)
OPK : 2.10 (-3.46%)
MNK : 2.66 (+4.31%)
NKTR : 17.27 (-2.81%)
AMAG : 11.20 (-1.88%)
Moleculin Announces Completion of Lymphoma Trial Enrollment

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.07 (-0.93%)
Advancements for Global Oncology and Cancer Drugs Market Expected to Show High Growth Potential

According to an industry report, the global oncology/cancer drugs market (which was valued at $97,401 Million in 2017) is estimated to reach at $176,509 Million by 2025, registering a CAGR of 7.6% from...

MBRX : 1.07 (-0.93%)
ALLK : 72.61 (-0.67%)
ITCI : 8.28 (-2.59%)
IMGN : 2.41 (-3.01%)
ENDP : 4.88 (+0.93%)
Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.07 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade MBRX with:

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

2nd Resistance Point 1.17
1st Resistance Point 1.12
Last Price 1.07
1st Support Level 1.04
2nd Support Level 1.01

See More

52-Week High 3.15
Fibonacci 61.8% 2.24
Fibonacci 50% 1.96
Fibonacci 38.2% 1.68
Last Price 1.07
52-Week Low 0.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar